A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O 6-Methylguanine-DNA Methyltransferase Promoter
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Responses of patients with gliomas to temozolomide are determined by O6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair (MMR) pathways. This phase II study (NCT00423150) investigated whether MGMT promoter methylation predicts response in patients with advanced aerodigestive tract and colorectal cancers (CRC). Tumor and serum samples were screened for MGMT promoter methylation. In methylation-positive patients, 150 mg/m2 temozolomide was administered daily on a seven-day-on, seven-day-off schedule for each 28-day cycle. The primary efficacy endpoint was response rate (RR). MMR status was determined by a microsatellite instability assay. Among 740 patients screened, 86 were positive for MGMT promoter methylation and enrolled. Nineteen percent of the screened population (137/740) had confirmed tissue and/or serum MGMT promoter methylation, including 25% (57 of 229) for CRC, 36% (55 of 154) for esophageal cancer, 11% (12 of 113) for head and neck cancer, and 5% (13 of 242) for non–small cell lung carcinoma. Among patients with valid methylation results in both tissue and serum samples, concordance was 81% (339 of 419). The majority of enrolled patients (69 of 86; 80%) had microsatellite stable cancer. Overall RR was 6% (5 of 86 partial responses); all responders had microsatellite stable cancer. Temozolomide resulted in low RRs in patients enriched for MGMT methylation. MGMT methylation status varied considerably in the patient population. Although serum methylation assay is an option for promoter methylation detection, tissue assay remains the standard for methylation detection. The low RR of this cohort of patients indicates that MGMT methylation as a biomarker is not applicable to heterogeneous tumor types, and tumor-specific factors may override validated biomarkers. Mol Cancer Ther; 12(5); 809–18. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Fluorescent Multiplex Assay for Detection of MSI‐High Tumors
Bacher, J. W., Flanagan, L. A., Smalley, R. L., Nassif, N. A., Burgart, L. J., Halberg, R. B., Megid, W. M. A., & Thibodeau, S. N. (2004) · Disease Markers · doi:10.1155/2004/136734 · Cited by 276
Cited by
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
“Although MGMT methylation is found in around 40% of colorectal cancers (CRCs), dacarbazine and its oral analog temozolomide yielded modest activity in selected patients with MGMT-methylated mCRC, with an overall response rate (ORR) , 10%.(9-14) Tumor responses to temozolomide are restricted to patients with concomitan…”
BackgroundMethylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Metadata
- Authors
- Hochhauser, D., Glynne-Jones, R., Potter, V., Grávalos, C., Doyle, T. J., Pathiraja, K., Zhang, Q., Zhang, L., & Sausville, E. A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2013-05-01
- Volume
- 12
- Issue
- 5
- Pages
- 809-818
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2107735114
- Cited by
- 57
- References
- 1
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O 6-Methylguanine-DNA Methyltransferase Promoter. https://app.cochat.ai/papers/10.1158/1535-7163.mct-12-0710
- The paper
- Hochhauser, D., Glynne-Jones, R., Potter, V., Grávalos, C., Doyle, T. J., Pathiraja, K., Zhang, Q., Zhang, L., & Sausville, E. A. (2013). A Phase II Study of Temozolomide in Patients with Advanced Aerodigestive Tract and Colorectal Cancers and Methylation of the O 6-Methylguanine-DNA Methyltransferase Promoter. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-12-0710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.